SLNO Soleno Therapeutics tops Q4 2025 EPS estimates by 103 percent shares edge 021 percent lower today Is Sabre Corporation SABR stock priced above intrinsic value Q4 2025 Profit Surprises Lam Research Corporation LRCX MATCH Act Policy Scrutiny Highlights China Exposure Risks Amid Contrasting Valuation and NearTerm Momentum